The US Food and Drug Administration (FDA) recommends Johnson & Johnson briefly ban the use of the anti-corona vaccine. The FDA has taken this step after the use of this vaccine revealed six cases of blood clotting. Let us know that even after the use of the Oxford-AstraZeneca vaccine Kovishield, there have been cases of abnormal blood clots.
According to the information, the United States has recommended a temporary ban on Johnson & Johnson's one-dose Kovid-19 vaccine to investigate reports of blood clotting.
The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) said in a joint statement on Tuesday that it is investigating reports of blood clotting and platelet counts decreasing in six women a few days after vaccination. . The statement said that more than 68 lakh doses of this vaccine have been given in the US, most of which have not seen any side effects.
Temporary prohibition will not apply to two vaccines
US federal distribution centers, including mass vaccination centers, will temporarily stop Johnson & Johnson's vaccine doses, and the provinces and other vaccinated parties are also expected to comply. However, the two other vaccines, Moderna and Pfizer, will not apply to this temporary moratorium.
The CDC Advisory Committee on Immunization will meet on Wednesday to discuss matters. Additionally, the FDA has also begun investigations into blood clotting and platelet counts.
CDC's Principal Deputy Director Dr. Annie Suchat and Dr. Peter Marks, Director of the FDA's Center for Biologics Evaluation and Research, said in a joint statement that until the process is complete, we are recommending a temporary ban on the use of this vaccine Huh.
What to do those who received the Johnson & Johnson vaccine?
They have suggested that people who are experiencing headaches, stomach pain, leg pain, or frequent breathing problems within three weeks after receiving the Johnson & Johnson vaccine, contact their healthcare provider.
The vaccine was approved for emergency use by the FDA in late February. It is noteworthy that concerns about blood clotting have so far only focused on the AstraZeneca vaccine, which has not yet been allowed to be used in the US.
The company dropped the stock
however, last week said European regulators reduce the number of vaccine doses and platelets in a very rare kind of explored a possible link between blood clots, which people under Are generated with.
It is noteworthy that Johnson & Johnson and AstraZeneca vaccines are made from the same technology. Shares of the company fell three percent following the announcement of a recommendation for a temporary moratorium on Johnson & Johnson vaccines.
The company will launch its vaccine in Europe late.
Johnson & Johnson company has said that it will delay its anti-Kovid-19 vaccine in Europe. The company said this in one of its statements amid the announcement of a US investigation into the case of blood clotting.